PMID- 10836281
OWN - NLM
STAT- MEDLINE
DCOM- 20000925
LR  - 20191025
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 15
IP  - 1
DP  - 2000 Jan
TI  - Long-term safety and efficacy of amisulpride in subchronic or chronic 
      schizophrenia. Amisulpride Study Group.
PG  - 13-22
AB  - Amisulpride is an atypical antipsychotic with selective affinity for dopamine 
      D2/3 receptors. In this long-term, open, randomised, multicentre trial, patients 
      with chronic or subchronic schizophrenia received amisulpride (n =370) or 
      haloperidol (n = 118) for 12 months. Dosage regimens were flexible (amisulpride 
      200-800 mg/day, haloperidol 5-20 mg/day). Improvement in mean Brief Psychiatric 
      Rating Scale total score was significantly greater for amisulpride than 
      haloperidol (17.0 versus 12.8, P = 0.01). Positive symptoms (Positive and 
      Negative Syndrome Scale [PANSS] positive) improved in a similar way in each group 
      but amisulpride caused a significantly better improvement in negative symptoms 
      (PANSS negative) (7.1 versus 3.7, P < 0.0001). Improvements in Global Assessment 
      of Functioning (GAF) and Quality of Life Scale (QLS) scores were also 
      significantly greater in the amisulpride group (GAF -20.1 versus -13.6, P = 
      0.001; QLS -0.64 versus -0.30, P = 0.02). Adverse events were mainly psychiatric 
      in nature, and occurred with similar frequency in each group (amisulpride 
      254/370, 69%; haloperidol 82/118, 70%). Extrapyramidal symptoms were more 
      frequent for haloperidol (48/118, 41% versus 96/370, 26% for amisulpride), 
      leading to a greater requirement for antiparkinsonian medication (haloperidol 
      66/118, 56% versus amisulpride 118/370, 32%). Haloperidol significantly 
      aggravated parkinsonism, akathisia and involuntary movement compared to 
      amisulpride. The overall incidence of endocrine events was comparable between 
      groups (4% for amisulpride, 3% for haloperidol). Maintenance of efficacy was 
      comparable in both treatment groups; 59% of amisulpride patients and 55% of 
      haloperidol patients improved after 1 month of therapy remained improved 
      throughout the study period. Amisulpride is effective following flexible 
      long-term administration and significantly improves social functioning and 
      quality of life.
FAU - Colonna, L
AU  - Colonna L
AD  - Unite de Psychiatrie,CHU Charles Nicolle, Rouen, France,
FAU - Saleem, P
AU  - Saleem P
FAU - Dondey-Nouvel, L
AU  - Dondey-Nouvel L
FAU - Rein, W
AU  - Rein W
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Antipsychotic Agents)
RN  - 7MNE9M8287 (Sulpiride)
RN  - 8110R61I4U (Amisulpride)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Amisulpride
MH  - Antipsychotic Agents/*adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Dyskinesia, Drug-Induced/epidemiology
MH  - Female
MH  - Haloperidol/adverse effects/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/*drug therapy
MH  - Sulpiride/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2000/06/03 09:00
MHDA- 2000/09/30 11:01
CRDT- 2000/06/03 09:00
PHST- 2000/06/03 09:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/06/03 09:00 [entrez]
AID - 10.1097/00004850-200015010-00002 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2000 Jan;15(1):13-22. doi: 
      10.1097/00004850-200015010-00002.